Senolytic Agents for Ocular Senescent Cell Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration are limited in their ability to address the underlying pathophysiology, often focusing on late-stage symptoms rather than the initial causes, and lack effective disease-modifying therapies.
Innovation Solution
Development of small molecule senolytic agents that target and eliminate senescent cells, which contribute to the progression of these diseases by reducing the abundance of senescent cells in the eye, thereby inhibiting neovascularization, vaso-obliteration, and increasing intraocular pressure, and using these agents to treat various ocular conditions through local or systemic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current VEGF inhibitors and symptom-relief drugs are used, then late-stage symptoms are treated, but the underlying pathophysiology and disease progression are not addressed
Solution Approach 1:
The patent applies preliminary action by targeting senescent cells before they can drive late-stage pathophysiology. Senolytic agents eliminate senescent cells early in the disease process, preventing the accumulation of these dysfunctional cells that would otherwise promote chronic inflammation, neovascularization, and tissue degradation. This upstream intervention addresses the root cause rather than downstream symptoms.
Solution Approach 2:
The patent applies the extraction principle by specifically removing senescent cells from the ocular tissue using senolytic agents. These agents selectively induce apoptosis in senescent cells while sparing healthy cells, thereby extracting the harmful cellular population that drives disease progression. This selective removal eliminates the source of pathogenic factors without broadly suppressing normal physiological processes.
2Reliability
If frequent treatment regimens are administered, then symptom relief is maintained, but patient burden and treatment complexity increase
Solution Approach 1:
The patent applies periodic action through extended-interval dosing of senolytic agents. Rather than requiring frequent administration like conventional therapies, senolytics achieve durable effects with dosing intervals extending from weeks to months. This periodic treatment schedule maintains therapeutic efficacy while dramatically reducing patient burden and improving compliance.
Solution Approach 2:
The patent applies partial action by using lower frequencies of administration that still achieve complete disease modification. A single course of senolytic treatment can eliminate sufficient senescent cell burden to provide long-lasting clinical benefit, making the treatment less burdensome while maintaining or exceeding the efficacy of frequent symptom-management regimens.
3Object-generated harmful factors
If VEGF inhibitors are used to treat neovascularization, then vascular growth is suppressed, but underlying senescent cell accumulation and inflammation persist
Solution Approach 1:
The patent applies extraction by removing senescent cells using senolytic agents. This eliminates the source of pro-inflammatory cytokines and growth factors secreted by senescent cells, thereby addressing the upstream driver of neovascularization and inflammation rather than merely blocking downstream VEGF signaling. The harmful senescent cell population is selectively extracted from the tissue.
Solution Approach 2:
The patent applies preliminary action by eliminating senescent cells before they can continuously stimulate neovascularization and inflammation. By removing the senescent cell burden upfront, the treatment prevents the chronic inflammatory state and abnormal angiogenesis that would otherwise develop or recur, addressing the root cause before secondary pathologies ensue.
Data Source
AI summary
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.